Alan M. Miller
A5066238218- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Colorectal and Anal Carcinomas
- Inflammatory Biomarkers in Disease Prognosis
- Esophageal Cancer Research and Treatment
- Hematopoietic Stem Cell Transplantation
- Lung Cancer Research Studies
- Acute Myeloid Leukemia Research
- Bladder and Urothelial Cancer Treatments
- Multiple and Secondary Primary Cancers
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Lung Cancer Treatments and Mutations
- Cytokine Signaling Pathways and Interactions
- Immune Response and Inflammation
- Cancer Cells and Metastasis
- Viral-associated cancers and disorders
- Immunotherapy and Immune Responses
- Eosinophilic Disorders and Syndromes
Translational Genomics Research Institute
2023-2024
Memorial Sloan Kettering Cancer Center
2016-2024
St. Vincent's HealthCare
2020-2023
Brown University
2019
Baylor College of Medicine
2017
Tulane University
1995-2016
University of Rochester Medical Center
2016
Mayo Clinic in Florida
2016
Columbia University Irving Medical Center
2016
Icahn School of Medicine at Mount Sinai
2016
We evaluated outcomes and associated prognostic factors in 233 patients undergoing allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis (MF) using reduced-intensity conditioning (RIC). The median age at RIC HCT was 55 yr. Donors were a matched sibling donor (MSD) 34% of HCTs, an HLA well-matched unrelated (URD) 45%, partially matched/mismatched URD 21%. Risk stratification according to the Dynamic International Prognostic Scoring System (DIPSS) 12% low, 49%...
A cute graft-versus-host disease remains a major threat to successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances resulted improved specifically among those diagnosed with acute disease. We examined following diagnosis of grade II-IV according time period, explored effects original prophylaxis regimen maximum overall Between 1999 2012, 2,905 patients myeloid leukemia...
Abstract Background Anti-PD-1 and PD-L1 (collectively PD-[L]1) therapies are approved for many advanced solid tumors. Biomarkers beyond immunohistochemistry, microsatellite instability, tumor mutation burden (TMB) may improve benefit prediction. Methods Using treatment data genomic transcriptomic tissue profiling from an observational trial (NCT03061305), we developed Immunotherapy Response Score (IRS), a pan-tumor predictive model of PD-(L)1 benefit. IRS real-world progression free survival...
Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approach is usual, starting with reduction in immunosuppressives (RI). The efficacy of RI remains poorly defined, particularly adults. We assessed an algorithm defined course all patients, escalating to interferon (IFN) alpha2b, and finally chemotherapy, prospective multicenter phase II study adult solid organ transplant recipients. design predated rituximab.
Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed chemotherapy-treated and might not be optimal for undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult reported to Center International Blood Marrow Transplant Research (CIBMTR) who underwent HCT AML first or second complete remission between 1999 2004. compared ability 6 stratify by...
To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell transplantation (allo HCT) for myelodysplastic syndrome (MDS).We examined 2,133 patients with MDS HLA-matched (n = 1,728) or -mismatched 405) allo HCT from 2000 to 2012. We used Cox multivariable model identify factors mortality training subset 1,151) the cohort. A weighted score using these was assigned remaining (validation cohort; n 577) as well HLA-mismatched HCT.Blood blasts greater than 3%...
Highlights1.We conducted the largest study comparing autologous hematopoietic cell transplantation with allogeneic in grades 1 and 2 follicular lymphoma rituximab era.2.In patients surviving years after transplantation, allografting provided an overall survival benefit.3.Rituximab resistance does not predict outcomes.4.Overall was better those performed from 2008 onward.5.Second hematological malignancies develop only a transplantation.AbstractThis to compare long-term outcomes...
Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ≥40 years receiving reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) HCT aggressive (n = 668) indolent 580) NHL. Aggressive was more frequent in the oldest cohort 49% 40 to 54 versus 57% 55 64 67% ≥65; P .0008). Fewer aged ≥65 had...
Tissue-based comprehensive genomic profiling (CGP) is increasingly used for treatment selection in patients with advanced cancer; however, tissue availability may limit widespread implementation. Here, we established real-world CGP and assessed performance on consecutively received samples.
To compare the clinical outcomes of older (age > or =55 years) non-Hodgkin lymphoma (NHL) patients with younger NHL (<55 receiving autologous hematopoietic cell transplantation (HCT) while adjusting for patient-, disease-, and treatment-related variables, we compared HCT in 805 aged years to 1949 <55 during 1990-2000 using data reported Center International Blood Marrow Transplant Research (CIBMTR). In multivariate analysis, aggressive histologies were 1.86 times (95% confidence interval...
The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported the Center for International Blood and Marrow Transplant Research who received a conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, umbilical cord blood donor 2000 2010....
We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed autologous transplantation. Nonrelapse mortality, progression/relapse, progression-free survival (PFS), overall were analyzed 263 lymphoma. All had a previous then undergone from related (n = 26) or unrelated 237) donor reduced-intensity 128) nonmyeloablative 135) reported to Center...
To have a better understanding of our patients' knowledge advance directive planning and execution, as well communication with their oncologists regarding wishes, we conducted survey on inpatient hematology-oncology services. A total 68 unique hospitalized patients diagnosis cancer completed surveys. Surveys were given to all oncology regardless reason for admission. Overall, 29% the reported having had discussion oncologist wishes if they became seriously ill or near death. Of those who did...
The in vitro incubation of cells from turpentine-induced rat myeloid hyperplastic marrow and peritoneal monocyte/macrophage with 14C-arachidonic acid resulted the incorporation radiolabel into particulate phospholipids. Challenge radiolabeled a highly purified type I CSF (CSF I) human pancreatic carcinoma continuous culture hydrolysis release cellular simultaneous challenge prelabeled CSF-I its specific antibody (anti-CSF-I antibody) inhibited induced cells. These results confer specificity...
Cancer care is expensive due to the high costs of treatment and preventable utilization resources. Government, employer groups, insurers are seeking cancer delivery models that promote both cost-efficiency quality care. Baylor University Medical Center at Dallas (BUMC), a large tertiary hospital, in collaboration with Texas Oncology, private oncology practice, established two independent centers function cooperatively within Charles A. Sammons Center, Oncology Evaluation Treatment (OETC)...
Prediction of subsequent leukemia-free survival (LFS) and chronic graft-versus-host disease (GVHD) in adults with acute leukemia who survived at least 1 year after allogeneic hematopoietic cell transplantation is difficult. We analyzed 3339 patients myeloid 1434 lymphoblastic received myeloablative conditioning related or unrelated stem cells from 1990 to 2005. Most clinical factors predictive LFS 1-year survivors were no longer significant 2 more years. For leukemia, only status (beyond...